Host Based Diagnostics for Acute Infections

The Capability Program Executive for Chemical, Biological, Radiological and Nuclear Defense (CPE CBRND) is issuing a Request for Information to identify scientifically mature, program‑viable host‑based diagnostic candidates (preferably TRL 4 or higher) that can rapidly diagnose acute infections, predict clinical outcomes, and guide therapeutic selection for warfighters exposed to CBRN threats. Submissions must include a three‑page white paper and a one‑page Quad Chart covering the project objective and benefit, a high‑level development schedule, rough order‑of‑magnitude cost, and any intellectual‑property or data‑rights considerations. Respondents should detail company profile and vision, corporate experience in advanced product development and licensure, and any teaming strategy, as well as current manufacturing capabilities, scalability plans, and supply‑chain sources for key materials. The envisioned device should be handheld or backpack‑sized, battery‑operable, tolerant of tropical humidity and temperature, deliver results in ≤70 minutes (ideally ≤10 minutes), and achieve ≥90 % clinical sensitivity and specificity using minimally invasive samples such as EDTA or PAXgene‑stabilized peripheral blood, finger‑stick blood, or respiratory specimens. This RFI is for market research only; it does not constitute a solicitation, promise of contract, or payment for information. Responses are to be sent to mcdc@ati.org with the subject line indicating the responding organization and RFI title, no later than 15:00 EST on 22 May 2026. The point of contact is Keith Pereira (keith.d.pereira.civ@army.mil).

Notice ID

af1504edae1a4c54a063505bca1f3c41

Solicitation Number

W911SR26RHDAI

NAICS Code

N/A

Classification Code

N/A